CNTX Context Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1842952 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-66.0%
TTM EPS YoY-91.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-84.3%
ROA-75.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets15.1%
Debt / equity0.00x
Current ratio6.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.72M | $12.53M | $7.02M | $11.84M | $8.72M | $7.83M | $3.46M | $2.52M |
| SG&A expense | $2.24M | $2.44M | $2.33M | $1.96M | $1.89M | $1.93M | $2.07M | $1.79M |
| Operating income | -$7.96M | -$14.97M | -$9.34M | -$13.80M | -$10.61M | -$9.76M | -$5.53M | -$4.31M |
| Net income | -$7.62M | -$14.56M | -$8.68M | -$13.03M | -$9.69M | -$8.83M | -$4.58M | -$3.34M |
| EBITDA | -$7.95M | -$14.96M | -$9.34M | -$13.80M | -$10.61M | -$9.75M | -$5.53M | -$4.31M |
| EPS (basic) | -0.08 | -0.15 | -0.09 | — | -0.10 | -0.09 | -0.05 | — |
| EPS (diluted) | -0.08 | -0.15 | -0.09 | — | -0.10 | -0.09 | -0.05 | — |
| Weighted avg. shares (diluted) | 95.18M | 95.18M | 95.18M | — | 95.19M | 95.19M | 95.19M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $34.41M | $42.99M | $54.53M | $66.00M | $76.94M | $83.52M | $89.35M | $94.43M |
| Current assets | $36.27M | $45.82M | $58.52M | $68.35M | $79.06M | $86.95M | $92.73M | $97.90M |
| PP&E, net | $66,599 | $74,068 | $62,227 | $29,656 | $33,721 | $37,787 | $41,852 | $11,959 |
| Total assets | $36.54M | $46.13M | $58.86M | $68.49M | $79.23M | $87.15M | $92.97M | $98.13M |
| Current liabilities | $5.50M | $7.88M | $6.53M | $8.02M | $6.04M | $4.56M | $1.90M | $2.75M |
| Total liabilities | $5.53M | $7.96M | $6.66M | $8.02M | $6.06M | $4.61M | $1.98M | $2.86M |
| Shareholders' equity | $31.01M | $38.17M | $52.20M | $60.47M | $73.17M | $82.54M | $90.98M | $95.27M |
| Shares outstanding | 91.88M | 91.88M | 91.88M | 91.88M | 91.88M | 89.70M | 89.70M | 89.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.58M | -$7.02M | -$11.43M | -$8.94M | -$6.58M | -$5.84M | -$5.03M | -$4.91M |
| Capital expenditure | $0 | $18,488 | $37,258 | $0 | $0 | $0 | $33,948 | $0 |
| Free cash flow | -$6.58M | -$7.04M | -$11.47M | -$8.94M | -$6.58M | -$5.84M | -$5.06M | -$4.91M |
| Investing cash flow | -$2.00M | -$4.52M | -$37,258 | -$2.00M | $0 | $0 | -$33,948 | $0 |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | -$15,268 | $14.54M |
| Depreciation & amortization | $7,469 | $6,647 | $4,687 | $4,065 | $4,066 | $4,065 | $4,055 | $2,934 |
| Stock-based compensation | $456,913 | $528,102 | $409,220 | $325,168 | $323,081 | $389,114 | $293,717 | $231,821 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.